A phase I/II trial to evaluate cabozantinib in patients with advanced hepatocellular carcinoma with Child-Pugh class B cirrhosis after first-line therapy.

Thomas Enzler,Neehar D. Parikh,Chih-Yi Liao,Aparna Kalyan,David Hsieh,Kent A. Griffith,Vaibhav Sahai

A phase I/II trial to evaluate cabozantinib in patients with advanced hepatocellular carcinoma with Child-Pugh class B cirrhosis after first-line therapy.

2021

Thomas Enzler
Neehar D. Parikh
Chih-Yi Liao
Aparna Kalyan
David Hsieh
Kent A. Griffith
Vaibhav Sahai

TPS357Background: Hepatocellular carcinoma (HCC) is the 4th leading cause of cancer related death worldwide. HCC typically develops in patients with cirrhosis and has a 5-year survival estimate of ...

Keywords:

Child-Pugh Class B
Internal medicine
Medicine
first line therapy
Cancer
Cirrhosis
Gastroenterology
in patient
Hepatocellular carcinoma
Cabozantinib
phase i ii

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations